Prior GHK-Cu studies showed it improves cognitive function in aged animals and counteracts oxidative stress relevant to AD pathogenesis
Tranexamic acid for spontaneous intracerebral hemorrhage: a randomized controlled pilot trial (ISRCTN50867461)
Mol Psychiatry 30 , 52155226 (2025)
In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: Injectable GLP-1s 2025 Ozempic for T2DM and peripheral artery disease (PAD) 2H 2025 Wegovy for heart failure with preserved ejection fraction (HFpEF) and obesity Oral GLP-1s October 2025 new indication for oral Rybelsus for secondary CV risk reduction 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape
Most patients need a combination approach: restoring structure (Sculptra and/or filler), improving skin quality (Skinvive, peels, skincare), and tightening where appropriate (Morpheus8)
The original scRNA- seq data generated in this study have been deposited in the gene expression omnibus (GEO) database under accession code GSE253271 The previously published data we used in this study are under accession code: GSE84133 42 , GSE203151 43
